| Literature DB >> 24913187 |
Diego F Cuadros1, Adam J Branscum, F DeWolfe Miller, Laith J Abu-Raddad.
Abstract
UNLABELLED: Egypt has the highest hepatitis C virus (HCV) prevalence in the world (14.7%). The drivers of the HCV epidemic in Egypt are not well understood, but the mass parenteral antischistosomal therapy (PAT) campaigns in the second half of the 20th century are believed to be the determinant of the high prevalence. We studied HCV exposure in Egypt at a microscale through spatial mapping and epidemiological description of HCV clustering. The source of data was the 2008 Egypt Demographic and Health Survey. We identified clusters with high and low HCV prevalence and high and low PAT exposure using Kulldorff spatial scan statistics. Correlations across clusters were estimated, and each cluster age-specific HCV prevalence was described. We identified six clusters of high HCV prevalence, three clusters of low HCV prevalence, five clusters of high PAT exposure, and four clusters of low PAT exposure. HCV prevalence and PAT exposure were not significantly associated across clusters (Pearson correlation coefficient [PCC] = 0.36; 95% confidence interval [CI] -0.12 to 0.71). Meanwhile, there was a strong association between HCV prevalence in individuals older than 30 years of age (who could have been exposed to PAT) and HCV prevalence in individuals 30 years of age or younger (who could not have been exposed to PAT) (PCC = 0.81; 95% CI 0.55-0.93).Entities:
Mesh:
Year: 2014 PMID: 24913187 PMCID: PMC4282472 DOI: 10.1002/hep.27248
Source DB: PubMed Journal: Hepatology ISSN: 0270-9139 Impact factor: 17.425
Hepatitis C Virus (HCV) and Parenteral Antischistosomal Therapy (PAT) Clustering Description
| Cluster | Fraction of the Population Within Cluster (%) | HCV Prevalence (%) | PAT Prevalence (%) | Relative | ||
|---|---|---|---|---|---|---|
| Clusters of high HCV prevalence | 2.6 (2.3-2.9) | 33.1 (27.7-38.8) | 17.8 (13.5-22.7) | 2.4 | <0.001 | |
| 4.1 (3.7-4.5) | 23.8 (19.9-30.0) | 12.8 (9.9-16.3) | 2.0 | <0.001 | ||
| 4.2 (3.8-4.6) | 23.4 (19.6-27.5) | 9.9 (7.3-13.0) | 1.7 | <0.001 | ||
| 2.5 (2.2-2.8) | 26.5 (21.4-32.1) | 14.1 (10.2-18.7) | 1.7 | <0.001 | ||
| 4.6 (4.3-5.1) | 22.3 (18.8-26.1) | 4.1 (2.6-6.2) | 1.6 | 0.0018 | ||
| 2.7(2.4-3.0) | 23.1 (18.5-28.4) | 9.7 (6.6-13.8) | 1.8 | 0.018 | ||
| Clusters of low HCV prevalence | 5.5 (5.1-6.0) | 7.5 (5.5-9.8) | 7.5 (5.5-9.9) | 0.5 | <0.001 | |
| 2.8 (2.5-3.1) | 9.4 (7.7-11.4) | 3.7 (2.6-5.0) | 0.7 | 0.011 | ||
| 9.3 (8.8-9.9) | 5.8 (3.5-9.0) | 9.1 (6.1-12.9) | 0.4 | 0.013 | ||
| Clusters of high PAT exposure | 2.8 (2.5-3.1) | 26.8 (21.9-32.1) | 24.1 (19.5-29.4) | 2.7 | <0.001 | |
| 3.4 (3.1-3.7) | 9.3 (6.6-12.7) | 19.5 (15.6-23.9) | 2.2 | <0.001 | ||
| 4.0 (3.6-4.3) | 18.0 (14.9-22.3) | 17.7 (14.2-21.7) | 2.0 | <0.001 | ||
| 12.4 (10.5-14.7) | 16.5 (10.8-23.8) | 22.3 (15.7-30.1) | 3.8 | <0.001 | ||
| 2.3 (2.0-2.6) | 9.5 (6.2-13.8) | 18.0 (13.4-23.3) | 2.0 | 0.026 | ||
| Clusters of low PAT exposure | 9.1 (8.6-9.7) | 10.6 (8.8-12.7) | 2.5 (1.6-3.7) | 0.3 | <0.001 | |
| 2.1 (1.9-2.4) | 6.7 (4.5-9.6) | 3.7 (2.0-6.0) | 0.4 | <0.001 | ||
| 5.3 (5.0-5.8) | 20.6 (17.4-24.0) | 3.3 (2.0-5.1) | 0.4 | <0.001 | ||
| 3.7 (3.4-4.1) | 12.2 (8.3-17.0) | 0 | 0.0 | <0.001 |
Includes HCV prevalence, PAT exposure, and P value for each identified cluster using spatial scan statistics. Clusters are organized in descending order starting from the most likely cluster.
Relative risk (RR) of HCV exposure for HCV clusters or RR of PAT exposure for PAT clusters.
Fig 2Comparisons and associations across clusters. (A) Comparison between hepatitis C virus (HCV) prevalence and parenteral antischistosomal therapy (PAT) exposure across all HCV exposure or PAT exposure clusters identified in this analysis. (B) Comparison between HCV prevalence among individuals 30 years old and older and HCV prevalence among individuals younger than 30 years in clusters of high and low HCV prevalence and high and low PAT exposure. Correlations were determined using Pearson correlation coefficient (PCC).
Fig 3Patterns of the age-specific prevalence of hepatitis C virus (HCV) infection. Age-specific prevalence of HCV infection in (A) the national sample; (B) the high HCV prevalence Cluster 1, Beni Suef/Minya; (C) the high HCV prevalence Cluster 5, Monufia; and (D) all clusters of low parenteral antischistosomal therapy (PAT) exposure.
Fig 4Geographical distribution of the estimated average annual hepatitis C virus (HCV) incidence rate that has been experienced by the living adult Egyptian cohort.
Fig 1Geographical distribution of the clusters of high (A) and low (B) hepatitis C virus (HCV) prevalence, and of high (C) and low (D) parenteral antischistosomal therapy (PAT) exposure. The dots indicate locations where the surveys were conducted.